P2RY12 and cerebrovascular disorder: Nevertheless, due to patent expiration in 2011, enormous generic competition, and the lack of data regarding the use of novel P2Y12 antagonists post PCI for stable coronary artery disease and cerebrovascular disease, clopidogrel is still the most commonly prescribed P2Y12 antagonist [14].